Bye Bye Lipitor: 2011 Presents A Big Opportunity For Generic Drugs
Executive Summary
For the generic drug industry, 2011 is just about utopia, while for brand drug makers it marks the end of an era. With Pfizer's blockbuster statin Lipitor (atorvastatin) – the world's top-selling drug with more than $11 billion in sales – expected to go generic in the U.S. in November, it marks a symbolic shift from the blockbuster primary care glory days of the late 1990s to the highly genericized, highly fragmented market of today.
You may also be interested in...
The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall
Blockbusters like Stelara, Eliquis, Prolia and Ibrance are poised to lose US exclusivity over the next five years; pressure is mounting for industry to replenish the portfolio with the next high-growth brands.
FDA Reshuffles Office Of Generic Drugs To Improve Performance
The generic drug industry can expect more streamlined reviews as a result of FDA's reorganization of the Office of Generic Drugs, according to the agency.
FDA Reshuffles Office Of Generic Drugs To Improve Performance
The generic drug industry can expect more streamlined reviews as a result of FDA's reorganization of the Office of Generic Drugs, according to the agency.